KR20200059163A - Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract - Google Patents
Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract Download PDFInfo
- Publication number
- KR20200059163A KR20200059163A KR1020190147880A KR20190147880A KR20200059163A KR 20200059163 A KR20200059163 A KR 20200059163A KR 1020190147880 A KR1020190147880 A KR 1020190147880A KR 20190147880 A KR20190147880 A KR 20190147880A KR 20200059163 A KR20200059163 A KR 20200059163A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin damage
- present
- preventing
- composition
- Prior art date
Links
- 230000037380 skin damage Effects 0.000 title claims abstract description 25
- 241001260874 Sargassum horneri Species 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 45
- 239000000284 extract Substances 0.000 title description 34
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 239000002537 cosmetic Substances 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 208000012641 Pigmentation disease Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 206010015150 Erythema Diseases 0.000 claims description 3
- 206010051246 Photodermatosis Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 231100000321 erythema Toxicity 0.000 claims description 3
- 230000008845 photoaging Effects 0.000 claims description 3
- 208000007578 phototoxic dermatitis Diseases 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 241000097929 Porphyria Species 0.000 claims description 2
- 208000010642 Porphyrias Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000017983 photosensitivity disease Diseases 0.000 claims description 2
- 230000036620 skin dryness Effects 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 208000028990 Skin injury Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000011506 response to oxidative stress Effects 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 20
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- -1 carbohydrate compounds Chemical class 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006355 external stress Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001474374 Blennius Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000010975 amethyst Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 208000002440 photoallergic dermatitis Diseases 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Abstract
Description
본 발명은 괭생이모자반 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating skin damage caused by ultraviolet rays containing the extract of hoesaengjabanban.
피부는 사람의 장기 중 가장 바깥에 위치해 있으며, 세균, 바이러스, 물리적 손상, 자외선 등과 같은 외부환경에 대한 1차적인 보호장벽의 역할을 한다. 피부는 지속적인 외부 스트레스가 가해지는 경우 손상을 받기 쉽다. 이러한 외부 스트레스의 주요 원인으로는 자외선 노출, 배기가스, 황사, 환경오염물, 중금속, 온도변화, 미생물을 대표적인 예로 들 수 있으며, 이들은 주로 산화적 스트레스(oxidative stress)를 통하여 활성산소종(reactive oxygen species, ROS)을 생성함으로써, 항산화 방어체계를 붕괴시켜 세포 손상 및 사멸을 야기하게 된다.The skin is located on the outermost of the human organs, and serves as a primary protective barrier against the external environment such as bacteria, viruses, physical damage, and ultraviolet rays. The skin is susceptible to damage under constant external stress. The main causes of this external stress include ultraviolet exposure, exhaust gas, yellow sand, environmental pollutants, heavy metals, temperature changes, and microorganisms. These are mainly reactive oxygen species through oxidative stress. , ROS), disrupting the antioxidant defense system, causing cell damage and death.
외부 스트레스 중 태양광선 특히 자외선(ultraviolet, UV)은 활성산소종의 생성을 통하여 피부 세포 및 조직에 손상을 일으키며, 지속적인 스트레스는 생체내 거대분자인 지질의 과산화, 단백질 산화, DNA 산화, 단백 분해효소 활성화, 탄력섬유 손상, 멜라닌 생성반응, 염증반응, 면역기능 저하 등을 유발하며 궁극적으로 피부 노화 과정을 가속화하는 것으로 알려져 있다. Among external stresses, sunlight, especially ultraviolet rays (UV), causes damage to skin cells and tissues through the production of free radicals, and constant stress causes peroxidation, protein oxidation, DNA oxidation, and proteolytic enzymes of macromolecules in vivo. It is known to induce activation, elastic fiber damage, melanin production reaction, inflammatory reaction, and immune function decline, and ultimately accelerate the skin aging process.
특히, 자외선은 파장의 길이에 따라 장파장(UV-A, 320-400 nm), 중파장(UV-B, 290-320 nm), 단파장(UV-C, 200-290 nm)로 구분된다. 자외선 A는 피부 내 진피까지 도달하며 탄력 및 교원섬유의 변성으로 인한 피부탄력 감소, 피부위축, 주름형성, 색소침착, 광독성, 광알러지, 피부암 등을 유발할 수 있다. 자외선 B는 표피의 기저층 또는 진피의 상부까지 도달하며 다량으로 노출되는 경우 면역저하, 염증 악화, 피부각화, 홍반, 일광화상, 색소침착, DNA 손상, 피부암 등을 일으키게 된다. 자외선 A 및 자외선 B 조사 후 생체 내 활성산소의 증가 및 내인성 항산화 효소 및 항산화제들의 감소가 보고되고 있으며, 그 결과로 인하여 광노화 과정이 촉진되게 된다.In particular, ultraviolet rays are classified into long wavelengths (UV-A, 320-400 nm), medium wavelengths (UV-B, 290-320 nm), and short wavelengths (UV-C, 200-290 nm) depending on the length of the wavelength. Ultraviolet A reaches the dermis in the skin and can cause skin elasticity reduction, skin atrophy, wrinkle formation, pigmentation, phototoxicity, photoallergy, and skin cancer due to elasticity and degeneration of collagen fibers. Ultraviolet B reaches the base layer of the epidermis or the upper part of the dermis and when exposed to a large amount, it causes immunity reduction, exacerbation of inflammation, skin keratinization, erythema, sunburn, pigmentation, DNA damage, and skin cancer. After irradiation with UV A and UV B, an increase in free radicals in vivo and a decrease in endogenous antioxidant enzymes and antioxidants have been reported, and as a result, the photoaging process is promoted.
따라서, 외부 스트레스로부터 피부 세포를 보호하고 노화를 예방하기 위해서는 활성산소로 인한 산화적 스트레스를 억제하고, 활성산소를 효율적으로 제거할 수 있는 항산화 방어 강화가 중요하며, 최근에는 인체에 무해하고 보다 강력한 항산화력을 가진 천연 물질에 대한 연구가 활발하게 진행되고 있다.Therefore, in order to protect skin cells from external stress and prevent aging, it is important to suppress oxidative stress caused by free radicals and to strengthen antioxidant defenses that can effectively remove free radicals. Research into natural substances having antioxidant properties is actively being conducted.
본 발명자들은 자외선에 의한 피부손상 억제 및 항산화 효과를 가지면서 인체 부작용이 적은 새로운 천연물질을 개발하기 위해 노력한 결과, 괭생이모자반 열처리 에탄올 추출물이 항산화 효과뿐만 아니라 자외선에 의한 피부손상을 억제하는 효과를 나타낸다는 것을 규명함으로써 본 발명을 완성하였다.The present inventors tried to develop a new natural substance with less human side effects while suppressing skin damage caused by UV rays and having antioxidant effects. As a result, ethanol extract of Hoeseng azamaban heat treatment has an antioxidant effect as well as an effect of inhibiting skin damage caused by UV rays. The present invention was completed by clarifying that it is shown.
이에, 본 발명의 목적은 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 치료용 약제학적 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays including ethanol extract of heat-treated hoejapanjaban.
본 발명의 다른 목적은 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 개선용 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition for preventing or improving skin damage caused by ultraviolet rays containing ethanol extract of hoesaengjabanban.
본 발명의 또 다른 목적은 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving skin damage caused by ultraviolet rays containing ethanol extract of heat-treated hoejajangjaban.
본 발명의 또 다른 목적은 괭생이모자반 열처리 에탄올 추출물을 포함하는 항산화용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for antioxidant comprising a heat-treated ethanol extract of hoesaengjabanban.
본 발명은 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 치료용 약제학적 조성물, 피부손상 예방 또는 개선용 화장료 조성물 및 식품 조성물, 및 항산화용 조성물에 관한 것으로, 본 발명에 따른 괭생이모자반 열처리 에탄올 추출물은 항산화 및 자외선에 의한 피부손상을 억제하는 활성을 나타낸다.The present invention relates to a pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays, a cosmetic composition and food composition for preventing or improving skin damage, and a composition for antioxidant, comprising ethanol extract from heat treatment of hoesaengjaban, and according to the present invention Heat-treated ethanol extracts from raw azaleas have an activity of inhibiting skin damage caused by antioxidant and ultraviolet rays.
이하 본 발명을 더욱 자세히 설명하고자 한다. Hereinafter, the present invention will be described in more detail.
본 발명자들은 자외선에 의한 피부손상 억제 및 항산화 효과를 가지면서 인체 부작용이 적은 새로운 천연물질을 개발하기 위해 노력한 결과, 괭생이모자반 열처리 에탄올 추출물이 항산화 효과 뿐만 아니라 자외선에 의한 피부손상을 억제하는 효과를 나타낸다는 것을 규명하였다. The present inventors tried to develop a new natural substance with less human side effects while suppressing skin damage caused by UV rays and having antioxidant effects. As a result, ethanol extract of Hoeseng azamaban heat treatment not only has an antioxidant effect, but also an effect of suppressing skin damage caused by UV rays. It was clarified that it was shown.
괭생이모자반(Sargassum horneri)은 한국, 일본 및 중국 연안에 폭넓게 분포하고 있으며, 주요 서식 수심층은 3-5 m 내외 암반으로 1-5 m까지 성장한다. 배우체 수명은 1년이며 고갈·유실을 반복하는 다년생 해조류로 주 성장 시기는 2-5월까지이다. 괭생이모자반은 5개월 동안 부유 가능한 모자반으로써 엽체 기질에서 떨어져 나와 본래 서식지로부터 해상 수백 킬로(km)까지 이동이 가능하다. Sargassum horneri is widely distributed on the coasts of Korea, Japan, and China, and the main habitat is about 3-5 m of rock, and grows up to 1-5 m of rock. The life span of a sperm is 1 year and it is a perennial seaweed that repeats depletion and loss. Its main growth period is from February to May. Hoeseng's mother's hat is a floating mother's hat that can float for 5 months and can move away from the leaf matrix and travel hundreds of kilometers (km) from its native habitat.
본 발명의 일 양태는 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 치료용 약제학적 조성물에 관한 것이다. One aspect of the present invention relates to a pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays comprising ethanol extract of heat-treated hoejajangjaban.
본 명세서에서, 용어 "예방"은 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸리기 쉬운 경향이 있는 개체에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. As used herein, the term "prevention" means to suppress the occurrence of a disease or condition in an individual who has never been diagnosed as having a disease or condition, but is prone to such disease or disease.
본 명세서에서, 용어 "치료" 또는 "개선"은 개체에서 (a) 질환 또는 질병의 발전의 억제 (b) 질환 또는 질병의 경감 및 (c) 질환 또는 질환의 제거를 의미한다. 본 명세서에서, 용어 "개체"는 본 발명의 상기 조성물을 투여하여 증상이 호전될 수 있는 질환을 가진 인간을 포함한 원숭이, 소, 말, 돼지, 양, 개, 고양이, 래트, 마우스, 침팬지 등의 포유동물을 의미한다.As used herein, the term “treatment” or “improvement” refers to (a) inhibition of disease or disease development (b) alleviation of disease or disease and (c) elimination of disease or disease in an individual. In the present specification, the term "individual" refers to monkeys, cows, horses, pigs, sheep, dogs, cats, rats, mice, chimpanzees, etc., including humans with diseases that may improve symptoms by administering the composition of the present invention. Means a mammal.
본 발명의 괭생이모자반 열처리 에탄올 추출물은 괭생이모자반을 열처리한 에탄올을 용매로 하여 추출한 괭생이모자반 추출물일 수 있다. 상기 에탄올은 30 내지 90% 에탄올 수용액, 50 내지 80% 에탄올 수용액, 60 내지 80% 에탄올 수용액 또는 70 내지 80% 에탄올 수용액 또는 70% 에탄올 수용액일 수 있다. The heat-treated ethanol extract of hoe-saengjapan of the present invention may be a hoesaeng-jajaban extract extracted using ethanol obtained by heat-treating hoesaengjaban. The ethanol may be 30 to 90% ethanol aqueous solution, 50 to 80% ethanol aqueous solution, 60 to 80% ethanol aqueous solution or 70 to 80% ethanol aqueous solution or 70% ethanol aqueous solution.
용매로 사용한 상기 열처리 에탄올은 에탄올을 가열한 것으로서 50℃ 내지 90℃, 50℃ 내지 80℃, 50℃ 내지 75℃, 60℃ 내지 90℃, 60℃ 내지 80℃, 60℃ 내지 75℃, 65℃ 내지 90℃, 65℃ 내지 80℃ 또는 65℃ 내지 75℃의 에탄올을 본 발명의 추출물 제조에 사용할 수 있고, 예를 들어, 70℃의 에탄올을 본 발명의 추출물 제조에 사용할 수 있다. The heat-treated ethanol used as a solvent is ethanol heated as 50 ° C to 90 ° C, 50 ° C to 80 ° C, 50 ° C to 75 ° C, 60 ° C to 90 ° C, 60 ° C to 80 ° C, 60 ° C to 75 ° C, 65 ° C Ethanol of 90 ° C, 65 ° C to 80 ° C, or 65 ° C to 75 ° C can be used for the preparation of the extract of the present invention, for example, 70 ° C ethanol can be used for the preparation of the extract of the present invention.
상기 '추출물'은 용매 조추출물, 특정 용매 가용 추출물(용매 분획물) 및 용매 조추출물의 용매 분획물을 포함하며, 상기 괭생이모자반 열처리 에탄올 추출물은 용액, 농축물 및/또는 분말 상태일 수 있다.The 'extract' includes a solvent crude extract, a specific solvent soluble extract (solvent fraction) and a solvent fraction of the solvent crude extract, and the heat-treated ethanol extract of Hoeseng amethyst may be in solution, concentrate and / or powder form.
구체적으로, 본 명세서에서 사용되는 용어 '추출물'은 상술한 바와 같이 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. Specifically, the term 'extract' used in the present specification has a meaning commonly used as a crude extract in the art as described above, but broadly also includes a fraction in which an extract is additionally fractionated.
즉, 괭생이모자반 열처리 에탄올 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예를 들어, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 괭생이모자반 열처리 에탄올 추출물에 포함되는 것이다.That is, the heat-treated ethanol extract of hoesaeng amethyst is not only obtained by using the above-described extraction solvent, but also obtained by additionally applying a purification process. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods are also included in the heat-treated ethanol extract of hoesan amethyst of the present invention.
본 발명에서 이용되는 괭생이모자반 열처리 에탄올 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 농축물 및/또는 분말 상태로 제조될 수 있다.The heat-treated ethanol extract used in the present invention may be prepared in the form of a concentrate and / or powder by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
본 발명의 일 구현예에 따르면, 상기 조성물은 자외선으로부터 피부세포를 보호함으로써 자외선에 의한 피부손상을 억제시킨다. According to an embodiment of the present invention, the composition suppresses skin damage caused by ultraviolet rays by protecting skin cells from ultraviolet rays.
상기 자외선에 의한 피부손상은 피부염, 피부암, 피부건조, 알레르기, 습진, 홍반반응, 색소침착, 일광화상, 광노화, 만성광선피부염, 일광두드러기, 광독성 접촉피부염, 광알레르기성 접촉피부염, 포르피린증, 홍반성낭창 또는 단순포진일 수 있다. Skin damage caused by the ultraviolet rays is dermatitis, skin cancer, skin dryness, allergy, eczema, erythema reaction, pigmentation, sunburn, photoaging, chronic photodermatitis, sunscreen, phototoxic contact dermatitis, photoallergic contact dermatitis, porphyria, erythematous It can be lupus or herpes simplex.
본 발명에 있어서, 약제학적 조성물은 상기 괭생이모자반 열처리 에탄올 추출물 이외에 약제학적으로 허용되는 담체를 포함할 수 있다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 탄수화물류 화합물(예: 락토스, 아밀로스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 셀룰로스, 등), 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 염 용액, 알코올, 아라비아 고무, 식물성 기름(예: 옥수수 기름, 목화 종자유, 두유, 올리브유, 코코넛유), 폴리에틸렌 글리콜, 메틸 셀룰로스, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.In the present invention, the pharmaceutical composition may include a pharmaceutically acceptable carrier in addition to the heat-treated ethanol extract of the hoejajangjaban. The pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention is commonly used in the preparation, and carbohydrate compounds such as lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc. ), Acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, salt solution, alcohol, gum arabic, vegetable oil (e.g. corn oil, cotton Seed oil, soy milk, olive oil, coconut oil), polyethylene glycol, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil, and the like, but is not limited thereto. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있으며, 바람직하게는 비경구 투여, 보다 바람직하게는 도포에 의한 국부 투여 방식으로 적용될 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally, preferably parenteral administration, more preferably, can be applied by local administration by application.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 한편, 본 발명의 약제학적 조성물의 투여량은 바람직하게는 1일 당 0.001-100 ㎎/kg(체중)이다. 또한, 외용제인 경우에는 성인 기준으로 1.0 내지 3.0 ml의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다.Suitable dosages of the pharmaceutical compositions of the invention are variously prescribed by factors such as formulation method, mode of administration, patient's age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion, and response sensitivity. Can be. On the other hand, the dosage of the pharmaceutical composition of the present invention is preferably 0.001-100 mg / kg (body weight) per day. In addition, in the case of an external preparation, it is recommended to apply for 1 to 5 times a day in an amount of 1.0 to 3.0 ml on an adult basis and continue for at least 1 month.
다만, 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.However, the dosage is not intended to limit the scope of the present invention.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액, 시럽제 또는 유화액 형태이거나 엑스제, 산제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in a unit dose form by formulating using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily carried out by a person skilled in the art to which the present invention pertains. Or it can be manufactured by incorporating into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or may be in the form of ex-agent, powder, granule, tablet or capsule, and may further include a dispersant or stabilizer.
본 발명의 일 양태에 따르면, 본 발명은 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 개선용 화장료 조성물에 관한 것이다. According to an aspect of the present invention, the present invention relates to a cosmetic composition for preventing or improving skin damage caused by ultraviolet rays comprising ethanol extract of heat-treated hoejajangjaban.
본 발명에 있어서, 화장료 조성물은 상기 괭생이모자반 열처리 에탄올 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있다. 예를 들어, 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 화장료로서 허용되는 통상적인 보조제, 그리고 담체를 포함한다.In the present invention, the cosmetic composition may include ingredients commonly used in the cosmetic composition in addition to the heat-treated ethanol extract of the hoejajangjaban. For example, conventional adjuvants acceptable as cosmetic agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.
본 발명에 있어서, 화장료 조성물은 상기 괭생이모자반 열처리 에탄올 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있다. 예를 들어, 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 화장료로서 허용되는 통상적인 보조제, 그리고 담체를 포함한다.In the present invention, the cosmetic composition may include ingredients commonly used in the cosmetic composition in addition to the heat-treated ethanol extract of the hoejajangjaban. For example, conventional adjuvants acceptable as cosmetic agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.
상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 샴푸, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다.The cosmetic composition may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, etc. It is not limited to this. More specifically, it can be prepared in the form of a nutrition cream, astringent lotion, soft lotion, lotion, essence, shampoo, nutrition gel or massage cream.
상기 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. are used as carrier components. Can be used.
상기 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbon, Propellants such as propane / butane or dimethyl ether.
상기 화장료 조성물이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르 등이 이용될 수 있다.When the cosmetic composition is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan and the like can be used.
상기 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미결정 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 한천 또는 트라가칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspension agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used.
상기 화장료 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid as a carrier component Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 일 양태에 따르면, 본 발명은 괭생이모자반 열처리 에탄올 추출물을 포함하는 자외선에 의한 피부손상 예방 또는 개선용 식품 조성물에 관한 것이다.According to an aspect of the present invention, the present invention relates to a food composition for preventing or improving skin damage caused by ultraviolet rays, including heat-treated ethanol extract of Hoeseng amoeba.
상기 식품 조성물은 피부손상 예방 또는 개선을 위한 식품 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 음료, 껌, 차, 비타민 복합제, 침출차, 건강 식품류 등의 각종 식품류 및 분말, 과립, 정제, 캡슐 등의 건강기능식품의 형태로 사용할 수 있다.The food composition may be used in various ways, such as food for preventing or improving skin damage. Foods to which the extract of the present invention can be added include, for example, various types of foods such as beverages, gums, teas, vitamin complexes, leached teas, health foods, and health functional foods such as powders, granules, tablets, and capsules. Can be used.
상기 식품 조성물에 함유된 유효성분으로서 괭생이모자반 열처리 에탄올 추출물의 함량은 식품의 형태, 소망하는 용도 등에 따라 적절하게 특별한 제한이 없으며, 예를 들어, 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 mL를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.The content of the heat-treated ethanol extract of hoesaengjabanban as an active ingredient contained in the food composition is not particularly limited according to the type of food, desired use, etc., and can be added, for example, from 0.01 to 15% by weight of the total food weight. In addition, the healthy beverage composition may be added at a rate of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 mL.
본 발명의 식품 조성물은 지시된 비율로 필수 성분으로서 상기 괭생이모자반 열처리 에탄올 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. The food composition of the present invention, as an essential ingredient in the indicated ratio, contains the heat-treated ethanol extract of Hoeseng azaban, and there is no particular limitation on the liquid component, and various flavors or natural carbohydrates, etc. It can contain.
상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL당 일반적으로 약 1 내지 2 0g, 바람직하게는 약 5 내지 12 g이다. Examples of the natural carbohydrate include monosaccharides, such as disaccharides such as glucose and fructose, such as maltose, sucrose, and polysaccharides, such as conventional sugars such as dextrin and cyclodextrin. And sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (e.g., rebaudioside A, glycyrrhizine, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g per 100 mL of the composition of the present invention, preferably about 5-12 g.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 외에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 중요하지 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and It may contain salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. In addition, the compositions of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages. These ingredients can be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
예를 들어, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 블루베리 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink agent, in addition to the blueberry extract of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, wormworm extract, jujube extract, licorice extract, etc. are additionally added. Can be included.
본 발명의 다른 일 양태에 따르면, 본 발명은 괭생이모자반 열처리 에탄올 추출물을 포함하는 항산화용 화장료 조성물에 관한 것이다.According to another aspect of the present invention, the present invention relates to a cosmetic composition for antioxidant comprising a heat-treated ethanol extract of hoesaengjabanban.
상기 괭생이모자반 추출물은 우수한 활성산소종(Reactive oxygen species, ROS) 생성 저해 활성을 나타내므로 항산화 용도로 이용할 수 있다. The hoesaengjajaban extract can be used for antioxidant purposes because it exhibits excellent inhibitory activity for reactive oxygen species (ROS) production.
본 발명의 항산화용 화장료 조성물은 산화 상태를 억제 또는 제거하여 예방 또는 치료할 수 있는 다양한 항산화-관련 질환, 질병 또는 이상 상태에 적용될 수 있다. 본 발명의 조성물에 의해 예방 또는 치료될 수 있는 항산화-관련 질환은 아테롬성 동맥경화증, 관상동맥질환, 심장동맥 재협착, 재관류 손상, 파킨슨병 또는 알츠하이머 질환과 같은 신경변성 질환, 뇌졸중, 암, 피부노화, 심혈관 질환, 골다공증, 중추신경계 장애, 말초혈관 질환 및 호흡곤란 등을 포함하나 이에 한정되는 것은 아니다.The cosmetic composition for antioxidant of the present invention can be applied to various antioxidant-related diseases, diseases or abnormal conditions that can be prevented or treated by inhibiting or removing the oxidized state. Antioxidant-related diseases that can be prevented or treated by the compositions of the present invention include atherosclerosis, coronary artery disease, cardiac artery restenosis, reperfusion injury, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, stroke, cancer, and skin aging. , Cardiovascular disease, osteoporosis, central nervous system disorders, peripheral vascular disease and dyspnea.
본 발명의 괭생이모자반 열처리 에탄올 추출물은 강력한 항산화 작용을 통해서 자외선에 의한 산화적 스트레스에 대응하여 세포 보호 효과를 나타내 자외선에 의한 피부 손상을 효과적으로 예방 및 개선할 수 있으므로, 과도한 자외선 조사에 의해 유발가능한 각종 피부 질환을 예방 또는 개선에 유용하게 사용될 수 있다.The heat-treated ethanol extract of Hoeseng amoebaban of the present invention exhibits a cell protective effect in response to oxidative stress caused by ultraviolet rays through a powerful antioxidant action, and thus can effectively prevent and improve skin damage caused by ultraviolet rays, and thus may be caused by excessive ultraviolet irradiation. It can be usefully used to prevent or improve various skin diseases.
도 1은 UVB가 조사된 HacaT 세포에 대한 괭생이모자반 추출물들의 보호 효과를 나타낸 결과이다.
도 2는 UVB가 조사된 HacaT 세포에 대한 괭생이모자반 추출물들의 세포 내 ROS 생성 억제 효과를 나타낸 결과이다. 1 is a result showing the protective effect of hoesaengmojaban extract on UVB irradiated HacaT cells.
Figure 2 is a result showing the inhibitory effect of ROS production in the cells of hoesaengmojaban extract on UVB irradiated HacaT cells.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시 예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시 예에 의해 제한되지 않는다는 것은 당 업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only intended to illustrate the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
실시예Example
본 명세서 전체에 거쳐, 특정 물질의 농도를 나타내기 위하여 사용되는 “%"는 별도의 언급이 없는 한 고체/고체는 (중량/중량) %, 고체/액체는 (중량/부피) %, 그리고 액체/액체는 (부피/부피) %이다.Throughout this specification, “%” used to indicate the concentration of a specific substance is (% by weight / weight) in solids / solids, (% by weight / volume) in solids / solids, and liquid unless otherwise specified. / Liquid is (volume / volume)%.
실시예 1. 괭생이모자반(Example 1. Sargassum horneriSargassum horneri ) 유래 추출물 제조) Preparation of derived extract
괭생이모자반(Sargassum horneri, 이하 SH)의 건조된 시료 15 g을 70℃로 열처리한 70% 에탄올에서 12시간, 80% 메탄올 및 증류수(25℃, 100℃)에 24시간 동안 추출하였다. 이후 각각의 추출물을 원심분리하여 여과지(Whatman No.6)로 여과하였고, 농축 및 동결 건조를 진행하여 열처리된 70% 에탄올(SHEH), 80% 메탄올(SHM), 상온(SHW), 열수 추출물(SHH)을 획득하였다. 각 추출물의 수율은 아래의 식에 따라 계산하였다.15 g of dried samples of hoesaengjabanban ( Sargassum horneri , SH) was extracted in 70% ethanol heat-treated at 70 ° C for 12 hours, 80% methanol and distilled water (25 ° C, 100 ° C) for 24 hours. Then, each extract was centrifuged and filtered with filter paper (Whatman No. 6), and concentrated and freeze-dried to heat-treated 70% ethanol (SHEH), 80% methanol (SHM), room temperature (SHW), and hot water extract ( SHH). The yield of each extract was calculated according to the formula below.
수율 (%) = [동결건조 후 시료 무게(g)Х(사용된 용매의 양(L)/추출 전 건조 시료의 무게(g))] Х 100 Yield (%) = [Sample weight after freeze-drying (g) Х (amount of solvent used (L) / weight of dry sample before extraction (g))]
실시예 2. 괭생이모자반 유래 추출물의 특성 및 성분 분석Example 2. Analysis of the properties and components of the extract derived from hoesaengjabanban
괭생이모자반 추출물들의 단백질 함량은 Lowry 등 (1951)의 방법을 약간 변형하여 측정하였다. 시험관에 가수분해물 1 mL와 2N NaOH 100 μL를 혼합하여 100℃에서 10분간 가수분해시킨 후, Lowry reagent 1 mL를 첨가하여 암실에서 10분간 반응시켰다. 그 후, Folin-Ciocalteau reagent 0.1 mL를 첨가하여 30분간 암실에서 반응시킨 후, microplate reader를 이용하여 660 nm에서 흡광도를 측정하였다. Bovine serum albumin(BSA)를 이용하여 표준 검량곡선을 작성하였고, SHM 내에 포함되어 있는 단백질의 함량을 계산하였다. Protein content of hoesaengjabanban extract was measured by slightly modifying the method of Lowry et al. (1951). 1 mL of hydrolyzate and 100 μL of 2N NaOH were mixed in a test tube and hydrolyzed at 100 ° C. for 10 minutes, and then 1 mL of Lowry reagent was added to react in the dark for 10 minutes. Then, 0.1 mL of Folin-Ciocalteau reagent was added and reacted in the dark for 30 minutes, and absorbance was measured at 660 nm using a microplate reader. A standard calibration curve was prepared using Bovine serum albumin (BSA), and the protein content in SHM was calculated.
탄수화물 함량은 phenol sulfuric acid method로 측정하였다. 시험관에 가수분해물 1 mL와 80% phenol 용액 25 μL, 황산 2.5 mL를 혼합하여 상온에서 30분간 반응시킨 후, microplate reader를 이용하여 480 nm에서 흡광도를 측정하였다. Glucose를 이용하여 표준 검량곡선을 작성하였고, SHM 내에 포함된 탄수화물의 함량을 계산하였다.Carbohydrate content was measured by the phenol sulfuric acid method. After mixing 1 mL of hydrolyzate with 25 mL of 80% phenol solution and 2.5 mL of sulfuric acid in a test tube for 30 minutes at room temperature, the absorbance was measured at 480 nm using a microplate reader. A standard calibration curve was prepared using Glucose, and the content of carbohydrates contained in SHM was calculated.
페놀 함량은 Singleton 등(2009)의 방법을 약간 변형하여 측정하였다. 시험관에 가수분해물 40 μL와 Folin-Ciocalteau reagent 200 μL, 증류수 1160 μL를 혼합하였다. 이 후, 5분 이내에 20% sodium carbonate 600 μL를 첨가하여 상온에서 2시간 동안 반응시킨 후, microplate reader를 이용하여 720 nm에서 흡광도를 측정하였다. Gallic acid를 이용하여 표준 검량곡선을 작성하였고, SHM 내에 포함되어 있는 페놀의 함량을 계산하였다.The phenol content was measured by slightly modifying the method of Singleton et al. (2009). In a test tube, 40 μL of hydrolyzate, 200 μL of Folin-Ciocalteau reagent, and 1160 μL of distilled water were mixed. Thereafter, 600 μL of 20% sodium carbonate was added within 5 minutes to react for 2 hours at room temperature, and absorbance was measured at 720 nm using a microplate reader. A standard calibration curve was prepared using gallic acid, and the content of phenol contained in SHM was calculated.
19.70 ± 0.02
괭생이모자반으로부터 4가지 추출물을 제조하였고, 수율을 측정한 결과, 괭생이모자반 열수 추출물인 SHH가 가장 높은 수율을 보였고, SHEH의 경우, 높은 단백질 및 페놀 함량을 나타냈다. 그 외 SHW, SHH와 SHM은 유사한 단백질 함량, 당함량, 페놀 함량을 보였다. Four extracts were prepared from hoesaengjabanban, and as a result of measuring the yield, SHH, the hoesaengjaban hot water extract, showed the highest yield, and SHEH showed high protein and phenol content. In addition, SHW, SHH and SHM showed similar protein content, sugar content and phenol content.
일반적으로 해조류에 함유된 활성물질에는 페놀성 화합물에 당이 붙어 있는 배당체 형태의 폴리페놀이 다량존재하며, 그러한 활성물질을 추출하기 위해서는 메탄올이나 에탄올과 같은 어느 정도의 극성을 가진 용매를 사용하는 것이 적당한 것으로 알려져 있다. 따라서 SH의 경우에도 열처리된 에탄올을 이용하여 추출하였을 때, 단백질의 증가와 일반적인 해조류에 비해 다소 높은 페놀함량을 보였기 때문에 이러한 성분에 의해 생리활성 효능을 가질 것이라고 사료되었다.In general, a large amount of polyphenol in the form of a glycoside with sugar attached to a phenolic compound is present in the active material contained in seaweed, and to extract such an active material, it is necessary to use a solvent having a certain polarity such as methanol or ethanol. It is known to be suitable. Therefore, in the case of SH, it was thought that when extracted using heat-treated ethanol, it would have a physiological activity effect by these ingredients because it showed a slightly higher phenol content than the protein and seaweed.
실시예 3. 괭생이모자반 추출물의 UV 보호 효능 스크리닝 및 기전 평가Example 3. Screening and mechanism evaluation of UV protection efficacy of Hoeseng amoebaban extract
한국세포주은행(KCLB, Seoul, Korea)으로부터 분양받은 인간 유래 피부각질형성세포인 HacaT 세포는 Penicillin/streptomycin 100 unit/mL과 10% FBS가 함유된 DMEM 배지를 사용하여 37℃ 5% CO2 incubator에서 배양하였으며 3일 간격으로 계대 배양을 시행하였다.HacaT cells, human-derived dermal keratinocytes from the Korea Cell Line Bank (KCLB, Seoul, Korea), were used in a DMEM medium containing Penicillin /
Hacat 세포에 대해 괭생이모자반 추출물들의 세포 보호효과를 측정하기 위해 thiazolyl blue tetrazolium bromide(MTT) assay를 실시하였다. Hacat 세포를 24 well plate에 1x105 cells로 분주하고 각 well에 10% FBS와 1% streptomycin과 penicillin이 포함되어 있는 DMEM 500 μL와 함께 37℃ 5% CO2 조건하에서 24시간 배양하였다. 그 후 샘플을 62.5 μg/mL의 농도로 처리하여 2시간 동안 배양한 후, UVB 40 mj/cm2로 자극하고 FBS가 없는 배지로 교체하였다. 48시간 후 상층액을 제거한 다음 dimethylsulfoxide(DMSO) 500 μL를 가하여 MTT의 환원에 의해 생성된 formazan 침전물을 용해시킨 후 microplate reader를 사용하여 570 nm에서 흡광도를 측정하였다. 생존율은 다음과 같은 식에 의해 계산하였다.A thiazolyl blue tetrazolium bromide (MTT) assay was performed to measure the cell protective effect of the extracts of Hoesengijaban on Hacat cells. Hacat cells were divided into 1x10 5 cells in a 24 well plate and cultured for 24 hours at 37 ° C 5% CO 2 with 500 μL of DMEM containing 10% FBS, 1% streptomycin and penicillin in each well. Thereafter, the sample was treated with a concentration of 62.5 μg / mL and incubated for 2 hours, then stimulated with
생존율(%) = [(UVB 처리군 또는 UVB + 샘플 처리군의 흡광도)/대조군의 흡광도]×100Survival rate (%) = [(UVB treated group or UVB + sample treated group absorbance) / control group absorbance] × 100
UVB를 조사한 Hacat 세포의 생존율 대한 괭생이모자반 추출물(SHEH, SHM, SHW 및 SHH)들의 보호효과를 확인하기 위해 MTT assay를 수행한 결과, Hacat 세포에 UVB를 처리하였을 때 아무것도 처리하지 않은 대조군에 비해 세포 생존율이 약 74%로 감소했으나, 괭생이모자반 추출물을 처리한 경우, 감소된 세포 생존율이 유의성 있게 증가하였다(도 1). 특히, SHEH의 경우, 다른 추출물과 비교 시 가장 우수하게 UVB 조사에 의해 감소된 세포 생존율을 향상시켰다.As a result of performing the MTT assay to confirm the protective effect of the extracts of hoezamojaban extracts (SHEH, SHM, SHW, and SHH) on the survival rate of Hacat cells irradiated with UVB, when the UVB was treated with Hacat cells, compared to the control group that did not process anything The cell viability was reduced to about 74%, but when treated with the extract of Hoesengjamojaban, the reduced cell viability was significantly increased (FIG. 1). In particular, in the case of SHEH, compared to other extracts, the cell viability reduced by UVB irradiation was best improved.
실시예 4. UVB가 조사된 Hacat 세포에서 괭생이모자반 추출물의 세포 내 ROS 생성 저해 활성 효과Example 4. Inhibitory activity effect of intracellular ROS production of Hoesengimojaban extract in UVB-irradiated Hacat cells
UVB 조사에 의해 활성화된 Hacat 세포의 세포 내 ROS(reactive oxygen species) 생성량에 대한 SHEH와 SHM의 억제 효능을 평가하기 위해 2', 7'- Dichlorofluorescin diacetate(DCFH-DA) assay를 수행하였다. Hacat 세포를 24 well plate에 1x105 cells로 분주하고 각 well에 10% FBS와 1% streptomycin과 penicillin이 포함되어 있는 DMEM 500 μL와 함께 37℃ 5% CO2 조건하에서 24시간 배양하였다. 그 후 SHM을 농도별(31.3-125 μg/mL)로 처리하여 2시간 동안 배양한 후, UVB 40 mj/cm2로 자극하고 FBS가 없는 배지로 교체하여 1시간동안 추가로 배양하였다. 그런 다음 0.5 mg/mL의 DCFH-DA 용액을 처리하여 30분 동안 배양 후, microplate reader를 이용하여 Excitation 485 nm/Emission 528 nm에서 측정하여 세포 내 ROS 생성량을 계산하였다. A 2 ', 7'-dichlorofluorescin diacetate (DCFH-DA) assay was performed to evaluate the inhibitory efficacy of SHEH and SHM on the intracellular ROS (reactive oxygen species) production of Hacat cells activated by UVB irradiation. Hacat cells were divided into 1x10 5 cells in a 24 well plate and cultured for 24 hours at 37 ° C 5% CO 2 with 500 μL of DMEM containing 10% FBS, 1% streptomycin and penicillin in each well. After that, the SHM was treated with concentrations (31.3-125 μg / mL) and incubated for 2 hours, then stimulated with
ROS 생성량 (%) = [(대조군 또는 샘플 처리군의 흡광도)/UVB만 처리한 군의 흡광도]×100ROS production (%) = [(absorbance of control or sample treatment group) / UVB-treated group absorbance] × 100
Hacat 세포에 UVB를 처리하여 생성된 세포 내 ROS에 대한 괭생이모자반 추출물들의 억제효능을 비교 평가한 결과, 세포에 UVB를 처리하였을 때 아무것도 처리하지 않은 대조군과 비교 시, 세포 내 ROS가 유의적으로 증가된 것을 확인 할 수 있었으나, SHEH와 SHM의 처리에 의해 UVB에 의해 증가된 세포 내 ROS 생성이 유의적으로 감소되었다(도 2). 특히, SHEH의 경우 125 μg/mL의 고농도에서 가장 우수하게 ROS 생성을 억제하였다. As a result of comparing and evaluating the inhibitory effect of the extracts of Hoesengjajaban on intracellular ROS generated by treating UVB on Hacat cells, when compared to the control group that did not process anything when UVB was treated on the cells, the intracellular ROS was significantly Although it could be confirmed that the increase, ROS production in cells increased by UVB was significantly reduced by treatment of SHEH and SHM (FIG. 2). In particular, in the case of SHEH, ROS production was suppressed at the highest concentration of 125 μg / mL.
상기 실험결과는 PASW Statistics 19.0 software(SPSS, Chicago, IL, USA)를 사용하여 통계적 유의성에 대하여 평가하였으며, 각 실험 군 간의 평균치의 유의성을 P < 0.05 수준에서 Duncan's test을 사용하여 비교하였다.The experimental results were evaluated for statistical significance using PASW Statistics 19.0 software (SPSS, Chicago, IL, USA), and the significance of the mean value between each experimental group was compared using Duncan's test at the P <0.05 level.
Claims (5)
Pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays, including heat-treated ethanol extract of Sargassum horneri .
The method of claim 1, wherein the skin damage caused by UV rays is dermatitis, skin cancer, skin dryness, allergy, eczema, erythema reaction, pigmentation, sunburn, photoaging, chronic photodermatitis, sunscreen, phototoxic contact dermatitis, photoallergic contact. Dermatitis, porphyria, erythematous lupus and herpes simplex or at least one skin injury selected from the group consisting of, pharmaceutical composition for preventing or treating skin damage caused by ultraviolet rays.
Sargassum horneri Cosmetic composition for preventing or improving skin damage caused by UV rays containing heat-treated ethanol extract.
Food composition for preventing or improving skin damage caused by ultraviolet rays, including heat treated ethanol extract of Sargassum horneri .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210136060A KR20210127677A (en) | 2018-11-20 | 2021-10-13 | Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180143894 | 2018-11-20 | ||
| KR20180143894 | 2018-11-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210136060A Division KR20210127677A (en) | 2018-11-20 | 2021-10-13 | Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200059163A true KR20200059163A (en) | 2020-05-28 |
Family
ID=70920458
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190147880A KR20200059163A (en) | 2018-11-20 | 2019-11-18 | Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract |
| KR1020210136060A KR20210127677A (en) | 2018-11-20 | 2021-10-13 | Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210136060A KR20210127677A (en) | 2018-11-20 | 2021-10-13 | Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR20200059163A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111632018A (en) * | 2020-06-12 | 2020-09-08 | 广东芭薇生物科技股份有限公司 | Composition containing hydrolyzed algae extract and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101613693B1 (en) | 2010-12-10 | 2016-04-19 | 부경대학교 산학협력단 | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same |
-
2019
- 2019-11-18 KR KR1020190147880A patent/KR20200059163A/en not_active IP Right Cessation
-
2021
- 2021-10-13 KR KR1020210136060A patent/KR20210127677A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111632018A (en) * | 2020-06-12 | 2020-09-08 | 广东芭薇生物科技股份有限公司 | Composition containing hydrolyzed algae extract and application thereof |
| CN111632018B (en) * | 2020-06-12 | 2022-05-27 | 广东芭薇生物科技股份有限公司 | Composition containing hydrolyzed algae extract and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210127677A (en) | 2021-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
| KR102026407B1 (en) | A composition for antioxidating comprising extracts of fermented tenebrio molitor | |
| KR102443410B1 (en) | Composition for preventing and treating brain diseases caused by fine dust containing Ecklonia cava extract | |
| KR102016027B1 (en) | Cosmetics composition improving skin wrinkle and skin elasticity and cosmetics including the same | |
| KR102022622B1 (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
| KR101851284B1 (en) | Composition for Preventing Skin Aging and Improving Skin Wrinkle Comprising Extract of Perilla Leaf | |
| KR102158780B1 (en) | Composition for improving skin comprising natural material extract | |
| KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
| KR101904215B1 (en) | A composition for antioxidating and blocking ultraviolet comprising extracts of jujube seed | |
| KR20220112447A (en) | Composition for improving skin, comprising Elaeaqnus macrophylla Extract as effective components, Cosmetic composition and Food functional composition including the same | |
| KR20210127677A (en) | Composition for Preventing or Treating Skin Damage by Ultraviolet comprising Sargassum horneri Extract | |
| KR102159577B1 (en) | A composition for improving skin wrinkle comprising Vaccinium ashei leaves extract | |
| KR101686521B1 (en) | Composition for beauty of skin | |
| KR102011639B1 (en) | Composition for anti-oxidant, skin whitening and anti-wrinkle effect comprising Glehnia Radix leaf extract as effective component | |
| KR20210133936A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| KR101487942B1 (en) | The method for manufacturing panax ginseng composite by using the punica granatum concentrate for skin whitening, and the panax ginseng composite made by the method | |
| KR101695372B1 (en) | Composition for improving wrinkle and elasticity containing ribes nigrum extracts | |
| KR101959551B1 (en) | A composition for improving skin hypochromatism and protecting the skin from ultraviolet comprising apple mint extracts | |
| KR20120009708A (en) | Compositions for Improving Skin Conditions Comprising Afzelin as an Active Ingredient | |
| KR102373481B1 (en) | Composition for anti-oxidating and anti-wrinkle comprising peach extracts | |
| KR20210101572A (en) | Composition for preventing or improving skin damage by ultraviolet comprising compounds derived from Sargassum horneri extracts | |
| KR20190143578A (en) | Composition Comprising Enzyme Treated Extract of Red Ginseng and Gastrodia for Preventing or Improving Skin Wrinkle as Active Ingredient | |
| KR102326592B1 (en) | Method to extract natural product using dry ice and composition containing extract obtained therefrom | |
| KR102178779B1 (en) | Composition for regulating skin hypersensitivity comprising Callophyllis japonica extract | |
| KR102106767B1 (en) | Composition for UV protection containing polysaccharides extracted from processed Panax ginseng and Green tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X601 | Decision of rejection after re-examination |